Search

Your search keyword '"García-Noblejas, Ana"' showing total 26 results
Start Over Author "García-Noblejas, Ana" Search Limiters Available in Library Collection
26 results on '"García-Noblejas, Ana"'

1. P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL

Author

Maria Ribera, Josep, primary, Morgades, Mireia, additional, García-Calduch, Olga, additional, Sirvent, Maialen, additional, Buendía Ureña, Buenaventura, additional, Cervera, Marta, additional, Luzardo, Hugo, additional, Hernández Rivas, Jesus, additional, Sitges Arriaga, Marta, additional, Garcia Cadenas, Irene, additional, Abrisquet Acosta, Pablo, additional, Montesinos, Pau, additional, Bastos Oreiro, Mariana, additional, Queipo de Llano, María-Paz, additional, Bravo, Pilar, additional, Torrent, Anna, additional, Puente, Maria Pilar Herrera, additional, Garcia-Guiñon, Antonio, additional, Vall-Llovera Calmet, Ferran, additional, Serrano, Josefina, additional, Terol, Maria J, additional, Burgues, Juan Miguel Bergua, additional, García-Noblejas, Ana, additional, Barrenetxea, Cristina, additional, Llorente, Laura, additional, García-Belmonte, Daniel, additional, Gimeno, Eva, additional, Cladera, Antonia, additional, Mercadal Vilchez, Santiago, additional, and Manuel Sancho, Juan, additional

Published
2023
Full Text
View/download PDF

2. Clinical outcomes after CPX ‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Author

Bernal, Teresa, primary, Moreno, Ainhoa Fernández, additional, de LaIglesia, Almudena, additional, Benavente, Celina, additional, García‐Noblejas, Ana, additional, Belmonte, Daniel García, additional, Riaza, Rosalía, additional, Salamero, Olga, additional, Foncillas, Maria Angeles, additional, Roldán, Alicia, additional, Concepción, Víctor Noriega, additional, González, Laura Llorente, additional, Bergua Burgués, Juan Miguel, additional, Lorente de Uña, Soraya, additional, Rodríguez‐Macías, Gabriela, additional, de la Fuente Burguera, Adolfo, additional, García Pérez, Maria José, additional, López‐Lorenzo, Jose Luis, additional, Martínez, Pilar, additional, Aláez, Concepción, additional, Callejas, Marta, additional, Martínez‐Chamorro, Carmen, additional, Roca, José Rifón, additional, Barciela, Lourdes Amador, additional, Mena Durán, Armando V., additional, Gómez Correcha, Karoll, additional, Lavilla Rubira, Esperanza, additional, Amigo, María Luz, additional, Vall‐llovera, Ferran, additional, Garrido, Ana, additional, García‐Fortes, María, additional, de Miguel Llorente, Dunia, additional, Leonardo, Anastasia Aules, additional, Cervero, Carlos, additional, Jordá, Rosa Coll, additional, Pérez‐Encinas, Manuel M., additional, Zarzuela, Marta Polo, additional, Figuera, Angela, additional, Rad, Guillermo, additional, Martínez‐Cuadrón, David, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

3. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico

Author

Orti, Guillermo, Sanz, Jaime, Bermudez, Arancha, Caballero, Dolores, Martinez, Carmen, Sierra, Jorge, Cabrera Marin, José R., Espigado, Ildefonso, Solano, Carlos, Ferrà, Christelle, García-Noblejas, Ana, Jimenez, Santiago, Sampol, Antonia, Yañez, Lucrecia, García-Gutiérrez, Valentin, Pascual, Maria Jesus, Jurado, Manuel, Moraleda, José M., Valcarcel, David, Sanz, Miguel A., Carreras, Enric, and Duarte, Rafael F.

Published
2016
Full Text
View/download PDF

6. Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source

Author

Ferrá, Christelle, Sanz, Jaime, de la Cámara, Rafael, Sanz, Guillermo, Bermúdez, Arancha, Valcárcel, David, Rovira, Montserrat, Serrano, David, Caballero, Dolores, Espigado, Ildefonso, Morgades, Mireia, Heras, Inmaculada, Solano, Carlos, Duarte, Rafael, Barrenetxea, Cristina, García-Noblejas, Ana, Díez-Martin, José L., Iriondo, Arturo, Carreras, Enric, Sierra, Jordi, Sanz, Miguel-Ángel, and Ribera, Josep-Maria

Published
2010
Full Text
View/download PDF

8. Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Author

Pérez-Lamas, Lucía, primary, Luna, Alejandro, additional, Boque, Concepcion, additional, Giraldo, Pilar, additional, Xicoy, Blanca, additional, Casado, Luis Felipe, additional, Sanchez-Guijo, Fermin, additional, Ruiz Nuño, Concepción, additional, Moreno Vega, Melania, additional, Alvarez-Larran, Alberto, additional, Salamanca Cuenca, Araceli, additional, García-Noblejas, Ana, additional, Vall-Llovera, Ferran, additional, Perez Encinas, Manuel, additional, Villalon, Lucia, additional, De las Heras, Natalia, additional, Lakhwani, Sunil, additional, Ramila, Elena, additional, Cuevas, Beatriz, additional, Perez Lopez, Raul, additional, Jiménez-Velasco, Antonio, additional, Rosell, Ana, additional, Escola, Angeles, additional, Fernández, Maria Jose, additional, Garcia-Hernandez, Carmen, additional, Cervero, Carlos, additional, Mora Casterá, Elvira, additional, Sagüés, Miguel, additional, Suarez-Varela, Sara, additional, Vélez, Patricia, additional, Carrascosa Mastell, Patricia, additional, Fé Bitaube, Rocio, additional, Serrano, Luis, additional, Cortes, Montse, additional, Juan Vera Goñi, Juan Antonio, additional, Steegmann, Juan Luis, additional, Hernandez Boluda, Juan Carlos, additional, Gomez, Valle, additional, Alonso-Dominguez, Juan Manuel, additional, Araujo, Mercedes Colorado, additional, Paz Coll, Antonio, additional, and Garcia Gutierrez, Valentín, additional

Published
2021
Full Text
View/download PDF

9. Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Author

Marin Niebla, Ana, Bastos-Oreiro, Mariana, Cabirta Touzón, Alba, Canelo Vilaseca, Marta, Sancho, Juan-Manuel, Jimenez Ubieto, Ana, Sáez Marín, Adolfo Jesús, Garcia Noblejas, Ana, Prieto Martinez, Pablo, Nicolas, Concepcion, Grande Garcia, Carlos, Luzardo Henriquez, Hugo Daniel, Hernandez Rivas, Jose Angel, Muntanola, Ana, Alonso Trillo, Rosalia, Arnaiz, Irene, Donato, Eva, Villafuerte Gutierrez, Paola, Garcia Belmonte, Daniel, Roldan Perez, Alicia, Suarez Ordonez, Sandra, Navarro Garces, Víctor, Bosch, Francesc, and Abrisqueta, Pau

Published
2023
Full Text
View/download PDF

10. Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo

Author

Huguet, Maria, Méndez, Aleix, Sanchez-Gonzalez, Blanca, Bastos-Oreiro, Mariana, Garcia-Sanz, Ramon, Romero, Samuel, Vidal-Manceñido, María-Jesús, Gutiérrez, Antonio, Villafuerte Gutierrez, Paola, Garcia Noblejas, Ana, Tapia, Gustavo, Sancho, Juan-Manuel, Ribera, Josep-Maria, and Navarro, José-Tomás

Published
2023
Full Text
View/download PDF

11. Fomento del talento, según Ken Róbinson. Inquietudes del adolescente y actividades de búsqueda de la vocación profesional

Author

Poveda-García-Noblejas, Ana María

Subjects
Ken Robinson, educación secundaria, vocación profesional, talento adolescentes, Máster Universitario en Formación de Profesorado de Educación Secundaria Especialidad Biología y Geología
Abstract

Los adelantos tecnológicos que acontecen a gran velocidad, unidos a la globalización, y la crisis económica, han provocado un cambio en las necesidades humanas que parece requerir una renovación del sistema educativo. El presente trabajo tiene como objetivo investigar acerca de la visión de los jóvenes sobre sí mismos y sobre su entorno, con el fin de descubrir sus inquietudes, así como la creación de un marco de actuación para ayudar al alumno de cara a la elección de unos estudios y un itinerario profesional. Para este propósito se ha realizado una encuesta en la que han participado 39 estudiantes de Educación Secundaria Obligatoria (ESO) y Bachillerato. Con los datos obtenidos, se han podido conocer las inquietudes de los adolescentes en diversos campos. Posteriormente, y guiados por las ideas de Ken Robinson en su libro “El Elemento”, así como revisando la bibliografía existente en cuanto a cuestionarios y test de orientación académica y profesional, se han creado tres actividades orientadas a la búsqueda de la propia vocación profesional para alumnos de cuarto de ESO y Bachillerato. Con vistas a una futura investigación más completa, estos ejercicios deberán ser perfeccionados y completados con asesoramiento del departamento de orientación y se deberán poner en práctica, de manera que pueda determinarse su eficacia.

Published
2013

12. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Author

Sureda, Anna, Canals, Carme, Arranz, Reyes, Caballero, Dolores, Ribera, Jose-Maria, Brune, Mats, Passweg, Jacob, Martino Bofarull, Rodrigo, Valcárcel, David, Besalduch, Joan, Duarte, Rafael, León, Angel, Pascual, Maria Jesús, García-Noblejas, Ana, López Corral, Lucia, Xicoy, Blanca, Sierra Gil, Jordi, Schmitz, Norbert, Universitat Autònoma de Barcelona, [Sureda,A, Martino,R, Valcárcel,D, Sierra,J] Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Sureda,A] Department of Haematology, Addenbrooke’s Hospital, Cambridge, UK. [Canals,C] EBMT Office, Barcelona, Spain. [Arranz,R, García-Noblejas,A] Hematology Department, Hospital de la Princesa, Madrid, Spain. [Caballero,D, Lopez Corral,L] Hematology Department, Hospital Clínico Universitario, Salamanca, Spain. [Ribera,JM, and Xicoy,B] Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Spain. [Brune,M] Hematology Section, Sahlgrenska University Hospital, Göteborg, Sweden. [Passweg,J] Departement Medecine Interne, Hopitaux Universitaires de Geneve, Geneve, Switzerland. [Besalduch,J] Hematology Department, Hospital Son Dureta, Palma de Mallorca, Spain. [Duarte,R] Institut Català d’Oncologia, L’Hospitalet de Llobregat, Spain. [León,A] Hematology Department, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain. [Pascual,MJ] Hematology Department, Hospital Carlos Haya, Málaga, Spain. [Schmitz,N] Hematology/Oncology Department, Asklepios Klinik St. Georg, Hamburg, Germany.

Subjects
Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings], Male, Transplantation Conditioning, Graft vs Host Disease, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Gastroenterology, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Autologous stem-cell transplantation, allogeneic stem cell transplantation, Estudios prospectivos, Secondary Prevention, Prospective Studies, Geographicals::Geographic Locations::Europe [Medical Subject Headings], Hematology, Middle Aged, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression::Transplantation Conditioning [Medical Subject Headings], Hodgkin Disease, Fludarabine, Europe, Survival Rate, Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings], Enfermedad de Hodgkin, Female, Acondicionamiento para el trasplante, medicine.drug, Adult, medicine.medical_specialty, Allogeneic transplantation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings], Adolescent, Check Tags::Male [Medical Subject Headings], Young Adult, reduced intensity conditioning, Internal medicine, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Cell Transplantation [Medical Subject Headings], medicine, Refractory Hodgkin Lymphoma, Humans, Transplantation, Homologous, Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Hodgkin Disease [Medical Subject Headings], Survival rate, Hodgkin's lymphoma relapsed, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Survival Rate [Medical Subject Headings], business.industry, Allogeic stem cell transplantation, medicine.disease, Lymphoma, Surgery, Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings], Transplantation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Transplantation, Homologous [Medical Subject Headings], refractory, Check Tags::Female [Medical Subject Headings], enfermedad injerto contra huésped, Original Articles and Brief Reports, business, Stem Cell Transplantation
Abstract

Clinical Trial, Phase II; Journal Article; Multicenter Study; BACKGROUND Although Hodgkin's lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line chemotherapy or even after high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic stem cell transplantation in this setting. DESIGN AND METHODS In this phase II study 92 patients with relapsed Hodgkin's lymphoma and an HLA-identical sibling, a matched unrelated donor or a one antigen mismatched, unrelated donor were treated with salvage chemotherapy followed by reduced intensity allogeneic transplantation. Fourteen patients showed refractory disease and died from progressive lymphoma with a median overall survival after trial entry of 10 months (range, 6-17). Seventy-eight patients proceeded to allograft (unrelated donors, n=23). Fifty were allografted in complete or partial remission and 28 in stable disease. Fludarabine (150 mg/m(2) iv) and melphalan (140 mg/m(2) iv) were used as the conditioning regimen. Anti-thymocyte globulin was additionally used as graft-versus-host-disease prophylaxis for recipients of grafts from unrelated donors. RESULTS The non-relapse mortality rate was 8% at 100 days and 15% at 1 year. Relapse was the major cause of failure. The progression-free survival rate was 47% at 1 year and 18% at 4 years from trial entry. For the allografted population, the progression-free survival rate was 48% at 1 year and 24% at 4 years. Chronic graft-versus-host disease was associated with a lower incidence of relapse. Patients allografted in complete remission had a significantly better outcome. The overall survival rate was 71% at 1 year and 43% at 4 years. CONCLUSIONS Allogeneic stem cell transplantation can result in long-term progression-free survival in heavily pre-treated patients with Hodgkin's lymphoma. The reduced intensity conditioning approach significantly reduced non-relapse mortality; the high relapse rate represents the major remaining challenge in this setting. The HDR-Allo trial was registered in the European Clinical Trials Database (EUDRACT, https://eudract.ema.europa.eu/) with number 02-0036. Yes

Published
2012

14. Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Author

Cannata-Ortiz, Jimena, primary, Nicolás, Concepción, additional, García-Noblejas, Ana, additional, Lopez, Javier, additional, Sabin, Pilar, additional, Zamora, Pilar, additional, Requena, Maria José, additional, and Arranz, Reyes, additional

Published
2014
Full Text
View/download PDF

15. Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Author

García-Noblejas, Ana, primary, Conde, Eulogio, additional, Martín, Alejandro, additional, Vidal, María Jesús, additional, Rojas, Rafael, additional, Grande, Carlos, additional, Ramirez, María José, additional, Cannata-Ortiz, Jimena, additional, García-Ruiz, Juan Carlos, additional, Briones, Javier, additional, Lopez, Andrés, additional, Ríos Rull, Pablo, additional, Noriega, Victor, additional, Deben, Guillermo, additional, González Barca, Eva, additional, González de Villambrosia, Sonia, additional, Ferreiro, Jose Javier, additional, Lahuerta, Juan José, additional, Caballero, Maria Dolores, additional, and Arranz, Reyes, additional

Published
2014
Full Text
View/download PDF

17. Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT

Author

Orti, Guillermo, primary, Sanz, Jaime, additional, Bermudez, Arancha, additional, Caballero, Dolores, additional, Martinez, Carmen, additional, Sierra, Jordi, additional, Marin, José R. Cabrera, additional, Espigado, Ildefonso, additional, Solano, Carlos, additional, Ferrà, Christelle, additional, García-Noblejas, Ana, additional, Jimenez, Santiago, additional, Sampol, Antonia, additional, Duarte, Monica Lopez, additional, Garcia, Valentin, additional, Pascual, Maria Jesus, additional, Jurado, Manuel, additional, Moraleda, José M., additional, Sanz, Miguel A., additional, Carreras, Enric, additional, and Duarte, Rafael F., additional

Published
2011
Full Text
View/download PDF

18. Myeloablative Conditioning with Intravenous Busulfan In One Daily Dose and Fludarabine (BUF) for HLA-Identical Sibling Allogeneic HSCT In Myeloid Malignancies

Author

De la Serna, Javier, primary, Sanz, Jaime, additional, Bermudez, Arancha, additional, Vallejo, Carlos, additional, Serrano, David, additional, Caballero, Dolores, additional, De La Camara, Rafael, additional, Moraleda, José M., additional, Gonzalez, Sonia, additional, García-Noblejas, Ana, additional, Cabrero, M., additional, Lahuerta, Juan José, additional, Iriondo, Arturo, additional, Benlloch, Luis, additional, and Sanz, Guillermo, additional

Published
2011
Full Text
View/download PDF

19. Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Author

García-Noblejas, Ana, primary, Navarro Matilla, Belén, additional, Da Silva Rodriguez, Carolina, additional, De Oña Navarrete, Raquel, additional, Ramirez Sánchez, María José, additional, Nicolás, Concepción, additional, Pérez Fernández, Ricardo, additional, Sanchez Gonzalez, Blanca, additional, Domingo-Domènech, Eva, additional, Sanchez Blanco, Jose Javier, additional, Cannata-Ortiz, Jimena, additional, González-López, Tomás José, additional, and Arranz Sáez, Reyes, additional

Published
2011
Full Text
View/download PDF

20. The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs. LNH-pro-05 trial)

Author

Cannata-Ortiz, Jimena, primary, Nicolás, Concepción, additional, García-Noblejas, Ana, additional, Lopez, Javier, additional, Requena, Maria José, additional, Alaez, Concepción, additional, Alegre, Adrian, additional, and Arranz, Reyes, additional

Published
2010
Full Text
View/download PDF

24. Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source.

Author

Ferra, Christelle, Sanz, Jaime, Camara, Rafael, Sanz, Guillermo, Bermudez, Arancha, Valcarcel, David, Rovira, Montserrat, Serrano, David, Caballero, Dolores, Espigado, Ildefonso, Morgades, Mireia, Heras, Inmaculada, Solano, Carlos, Barrenetxea, Cristina, Duarte, Rafael, Garcia-Noblejas, Ana, Diez, José Luis, Iriondo, Arturo, Carreras, Enric, Sierra, Jordi, Sanz, Miguel A., and Ribera, Josep M.

Published
2008
Full Text
View/download PDF

25. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Author

Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, and Caballero D

Subjects
Adult, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Murine-Derived administration & dosage, Cytarabine administration & dosage, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Lymphoma, Mantle-Cell diagnosis, Male, Methotrexate administration & dosage, Middle Aged, Pilot Projects, Prospective Studies, Rituximab, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Lymphoma, Mantle-Cell drug therapy, Lymphoma, Mantle-Cell epidemiology
Abstract

Unlabelled: The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue to appear. In this trial we evaluated the feasibility, safety and efficacy of rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine followed by consolidation with (90)Y-ibritumomab tiuxetan. Patients received six cycles followed by a single dose of (90)Y-ibritumomab tiuxetan. Thirty patients were enrolled; their median age was 59 years. Twenty-four patients finished the induction treatment, 23 achieved complete remission (77%, 95% confidence interval 60-93) and one patient had progressive disease (3%). Eighteen patients (60%), all in complete remission, received consolidation therapy. In the intent-to-treat population, failure-free, progression-free and overall survival rates at 4 years were 40% (95% confidence interval 20.4-59.6), 52% (95% confidence interval 32.4-71.6) and 81% (95% confidence interval 67.28-94.72), respectively. For patients who received consolidation, failure-free and overall survival rates were 55% (95% confidence interval 31.48-78.52) and 87% (95% confidence interval 70-100), respectively. Hematologic toxicity was significant during induction and responsible for one death (3.3%). After consolidation, grade 3-4 neutropenia and thrombocytopenia were observed in 72% and 83% of patients, with a median duration of 5 and 12 weeks, respectively. Six (20%) patients died, three due to secondary malignancies (myelodysplastic syndrome and bladder and rectum carcinomas). In conclusion, in our experience, rituximab-hyperCVAD alternated with rituximab-methotrexate-cytarabine and followed by consolidation with (90)Y-ibritumomab tiuxetan was efficacious although less feasible than expected. The unacceptable toxicity observed, especially secondary malignancies, advise against the use of this strategy., Trial Registration: clinical.gov identifier: NCT2005-004400-37.

Published
2013
Full Text
View/download PDF

26. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Author

Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, and Schmitz N

Subjects
Adolescent, Adult, Europe, Female, Graft vs Host Disease immunology, Graft vs Host Disease mortality, Hodgkin Disease immunology, Hodgkin Disease mortality, Humans, Male, Middle Aged, Prospective Studies, Secondary Prevention, Stem Cell Transplantation mortality, Survival Rate, Transplantation Conditioning mortality, Transplantation, Homologous mortality, Young Adult, Hodgkin Disease surgery, Stem Cell Transplantation methods, Transplantation Conditioning methods
Abstract

Background: Although Hodgkin's lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line chemotherapy or even after high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic stem cell transplantation in this setting., Design and Methods: In this phase II study 92 patients with relapsed Hodgkin's lymphoma and an HLA-identical sibling, a matched unrelated donor or a one antigen mismatched, unrelated donor were treated with salvage chemotherapy followed by reduced intensity allogeneic transplantation. Fourteen patients showed refractory disease and died from progressive lymphoma with a median overall survival after trial entry of 10 months (range, 6-17). Seventy-eight patients proceeded to allograft (unrelated donors, n=23). Fifty were allografted in complete or partial remission and 28 in stable disease. Fludarabine (150 mg/m(2) iv) and melphalan (140 mg/m(2) iv) were used as the conditioning regimen. Anti-thymocyte globulin was additionally used as graft-versus-host-disease prophylaxis for recipients of grafts from unrelated donors., Results: The non-relapse mortality rate was 8% at 100 days and 15% at 1 year. Relapse was the major cause of failure. The progression-free survival rate was 47% at 1 year and 18% at 4 years from trial entry. For the allografted population, the progression-free survival rate was 48% at 1 year and 24% at 4 years. Chronic graft-versus-host disease was associated with a lower incidence of relapse. Patients allografted in complete remission had a significantly better outcome. The overall survival rate was 71% at 1 year and 43% at 4 years., Conclusions: Allogeneic stem cell transplantation can result in long-term progression-free survival in heavily pre-treated patients with Hodgkin's lymphoma. The reduced intensity conditioning approach significantly reduced non-relapse mortality; the high relapse rate represents the major remaining challenge in this setting. The HDR-Allo trial was registered in the European Clinical Trials Database (EUDRACT, https://eudract.ema.europa.eu/) with number 02-0036.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results